Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBT (2016 - 2025)

Ironwood Pharmaceuticals' EBT history spans 16 years, with the latest figure at -$83.4 million for Q4 2025.

  • For Q4 2025, EBT fell 447.65% year-over-year to -$83.4 million; the TTM value through Dec 2025 reached -$13.9 million, down 121.36%, while the annual FY2025 figure was $161.2 million, 147.18% up from the prior year.
  • EBT for Q4 2025 was -$83.4 million at Ironwood Pharmaceuticals, down from $68.0 million in the prior quarter.
  • Across five years, EBT topped out at $72.3 million in Q4 2022 and bottomed at -$1.1 billion in Q2 2023.
  • The 5-year median for EBT is $39.1 million (2021), against an average of -$33.5 million.
  • The largest annual shift saw EBT surged 1106.52% in 2021 before it plummeted 2100.97% in 2023.
  • A 5-year view of EBT shows it stood at $46.3 million in 2021, then skyrocketed by 56.23% to $72.3 million in 2022, then plummeted by 371.46% to -$196.2 million in 2023, then soared by 112.23% to $24.0 million in 2024, then plummeted by 447.65% to -$83.4 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's EBT are -$83.4 million (Q4 2025), $68.0 million (Q3 2025), and $37.8 million (Q2 2025).